I zoomed in a little closer and thought this might be a bit more accurate in either scenario.
I joined NKTR at the ~12.67 in Jan. 2017. I did not see this historical chart prior to selling early 2018, and then upping the ante throughout 2018, learning more about options contracts as well. Now that I am at a loss of ~$8K, with a cost basis in the mid-40's, I see that even though Bristol-Myers Squibb made a huge investment, the trend should continue...
As sales volume reduce, price downward cannot go further down to break lows, it can cause the price to go further up til 43$
Watch for the wedge breakout around Sept 28th. Should hit outlined target before earnings. Might move even higher.
This is looking good. And it seems like institutions are buying on volume.
Nice move from Double bottom 46$. above 63.05 could be a great player moving forward - GAP . Trying to push resistance 62.70$ (+ MA100. D) . support 61.21$ (MA200), & 58.50$
This look likes a bear set up going into earnings. I hope i'm wrong but not sure what good can come out of earning that would warrant a price pop?
Ok this is a $$$ bill playing move right here potentially. If it breaks this 58 level it will move straight to the 100MA on the weekly chart. That's a $13 move!. If it bounces off the 58 level it should retest the 64ish level. Lets all pray for the break lower.
This is gapping down off a huge white candle trapping everybody!! If it gaps below my entry line I like this trader to the 200MA.. If it gets below that I have another exit which this based off the weekly chart.
Short from 103.5 but expect some further buying could see some profit taking by institutions over coming months. - $1bn short interest - 189.82 price to book ratio shows the inflated share price. - 1.96 beta - Considering its returned 549.33% in the past year and is already up 70.81% YTD and is 97.28% institutionally owned is of concern if earnings miss...
Idea. Going to wait